Heart failure & cardiomyopathiesSecondary analysis
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Secondary analysis of the DELIVER randomised trial
- post hoc exploratory analysis
- double-blind
- placebo-controlled
- 353 centres in 20 countries
Authors' conclusion
In this study of patients with HF with mildly reduced or preserved ejection fraction, dapagliflozin was associated with improvement in a broad range of individual KCCQ components, with the greatest benefits in domains related to symptom frequency and physical limitations.
Study context
- Population
- Symptomatic heart failure (HF) with LVEF >40%, elevated natriuretic peptides and structural heart disease5,795 with baseline Kansas City Cardiomyopathy Questionnaire (KCCQ)
- Participants
- 6,263 participants
- Comparison
- Dapagliflozin vs placebo
- Primary endpoint
- Changes in the 23 individual KCCQ components (scaled 0–100)
- Follow-up
- 8 months
Primary result
As reported in the abstract
Individual KCCQ components
Dapagliflozin vs PlaceboDifference (95% CI)P value
frequency of lower limb edema
3.2(1.6–4.8)
P < 0.001sleep limitation by shortness of breath
3.0(1.6–4.4)
P < 0.001limitation in desired activities by shortness of breath
2.8(1.3–4.3)
P < 0.001Further findings
KCCQ components, longitudinal analysis (months 1, 4 and 8)
- Similar treatment patterns
Proportions improving or deteriorating
- More patients improved and fewer deteriorated with dapagliflozin across most components
Original publication
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. Published 1 July 2023. doi:10.1001/jamacardio.2023.1342
Summarised from the published abstract; every number is checked against it